Skip to main content

ScienceDex / Researcher record

Kampman, Kyle Matthew

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #1,710
  • Long-Funded
  • Top 10% Funded

NIH Funding · FY2023

$3.1M
Full award amounts, FY2023
2
Records listing this PI
#1,710
By linked amount among FY2023 PIs
2006
ScienceDex PI coverage

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

Linked awards ($M)Award-linked rank
View yearly values
Award-linked funding and rank by fiscal year
Fiscal yearLinked awardsRecordsRank
2006$549,2231#11,344
2007$1,041,3792#6,192
2008$1,249,2243#4,676
2009$529,9951#16,562
2010$515,3811#16,931
2011$957,4283#7,382
2012$335,5251#23,387
2013$2,125,9072#2,430
2014$1,864,2832#3,183
2015$1,784,0342#3,281
2016$1,574,0452#3,809
2017$1,001,2221#6,911
2018$1,203,0022#5,907
2019$4,303,3922#842
2023$3,117,4032#1,710

Award activity

Awards through the years

NIH award records listing this researcher in each fiscal year.

  1. FY20061 record
  2. FY20072 records
  3. FY20083 records
  4. FY20091 record
  5. FY20101 record
  6. FY20113 records
  7. FY20121 record
  8. FY20132 records
  9. FY20142 records
  10. FY20152 records
  11. FY20162 records
  12. FY20171 record
  13. FY20182 records
  14. FY20192 records
  15. FY2023 · selected2 records

Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Kampman, Kyle Matthew. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2023 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets About this stat →

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Publications

Loading publications…

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.

FY2023 award categories

  • Psychiatry

FY2023 award records by amount

NIH award records listing Kampman, Kyle Matthew as a PI. Multi-PI records show the full award amount for context.

  • 4UH3DA049694-02UH3Contact PI
    Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?
    University of Pennsylvania · Psychiatry (NIH department code)
    $2.9M
    award amount
  • 1R34DA057507-01A1R34Contact PI
    Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl
    University of Pennsylvania · Psychiatry (NIH department code)
    $232.8K
    award amount

Award organization

Organizations that administered FY2023 awards listing Kampman, Kyle Matthew as a PI.

FY2023 award administered by University of Pennsylvania (PA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2006
    First NIH Award
    University of Pennsylvania
  2. 2006
    $500K Cumulative Funding
  3. 2007
    $1M Cumulative Funding
  4. 2007
    Entered Top 50% Nationally
    Ranked #6192
  5. 2008
    $2M Cumulative Funding
  6. 2008
    Entered Top 25% Nationally
    Ranked #4676
  7. 2012
    $5M Cumulative Funding
  8. 2015
    $10M Cumulative Funding
  9. 2019
    Entered Top 10% Nationally
    Ranked #842
  10. 2019
    Entered Top 5% Nationally
    Ranked #842